BIOMAT Database Logo BIOMAT Database Logo

Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group. 1994

U Bruntsch, and B Heinrich, and S B Kaye, and P H de Mulder, and A van Oosterom, and R Paridaens, and J B Vermorken, and J Wanders, and H Franklin, and M Bayssas
5. Med Klinik, Nuremberg, Germany.

Docetaxel (Taxotere), an analogue of paclitaxel, was tested in a phase II study in advanced renal cell carcinoma. Consenting patients with measurable lesions, adequate organ functions and no prior chemotherapy received 100 mg/m2 of docetaxel as a 1-h infusion every 3 weeks. No premedication to avoid hypersensitivity reactions or nausea and emesis was given. 32 eligible patients received 100 treatment cycles. Short-lasting neutropenia was the dose-limiting toxicity. Acute hypersensitivity reactions (HSR), oedema and skin changes were other important side-effects. HSRs regressed spontaneously or were treated with antihistamines with or without corticosteroids. One partial remission was documented. At the dose and schedule used, docetaxel has only low activity against renal cell carcinoma.

UI MeSH Term Description Entries
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002292 Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma. Adenocarcinoma, Renal Cell,Carcinoma, Hypernephroid,Grawitz Tumor,Hypernephroma,Renal Carcinoma,Adenocarcinoma Of Kidney,Adenocarcinoma, Renal,Chromophil Renal Cell Carcinoma,Chromophobe Renal Cell Carcinoma,Clear Cell Renal Carcinoma,Clear Cell Renal Cell Carcinoma,Collecting Duct Carcinoma,Collecting Duct Carcinoma (Kidney),Collecting Duct Carcinoma of the Kidney,Nephroid Carcinoma,Papillary Renal Cell Carcinoma,Renal Cell Cancer,Renal Cell Carcinoma,Renal Cell Carcinoma, Papillary,Renal Collecting Duct Carcinoma,Sarcomatoid Renal Cell Carcinoma,Adenocarcinoma Of Kidneys,Adenocarcinomas, Renal Cell,Cancer, Renal Cell,Carcinoma, Collecting Duct,Carcinoma, Collecting Duct (Kidney),Carcinoma, Nephroid,Carcinoma, Renal,Carcinomas, Collecting Duct,Carcinomas, Collecting Duct (Kidney),Carcinomas, Renal Cell,Collecting Duct Carcinomas,Collecting Duct Carcinomas (Kidney),Hypernephroid Carcinoma,Hypernephroid Carcinomas,Hypernephromas,Kidney, Adenocarcinoma Of,Nephroid Carcinomas,Renal Adenocarcinoma,Renal Adenocarcinomas,Renal Carcinomas,Renal Cell Adenocarcinoma,Renal Cell Adenocarcinomas,Renal Cell Cancers,Renal Cell Carcinomas,Tumor, Grawitz
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077143 Docetaxel A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER. Docetaxel Anhydrous,Docetaxel Hydrate,Docetaxel Trihydrate,Docetaxol,N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol,NSC 628503,RP 56976,RP-56976,Taxoltere Metro,Taxotere,N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol,RP56976
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics

Related Publications

U Bruntsch, and B Heinrich, and S B Kaye, and P H de Mulder, and A van Oosterom, and R Paridaens, and J B Vermorken, and J Wanders, and H Franklin, and M Bayssas
Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.
August 1994, British journal of cancer,
U Bruntsch, and B Heinrich, and S B Kaye, and P H de Mulder, and A van Oosterom, and R Paridaens, and J B Vermorken, and J Wanders, and H Franklin, and M Bayssas
Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group.
January 1994, European journal of cancer (Oxford, England : 1990),
U Bruntsch, and B Heinrich, and S B Kaye, and P H de Mulder, and A van Oosterom, and R Paridaens, and J B Vermorken, and J Wanders, and H Franklin, and M Bayssas
Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)
August 1994, British journal of cancer,
U Bruntsch, and B Heinrich, and S B Kaye, and P H de Mulder, and A van Oosterom, and R Paridaens, and J B Vermorken, and J Wanders, and H Franklin, and M Bayssas
A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.
July 1994, Annals of oncology : official journal of the European Society for Medical Oncology,
U Bruntsch, and B Heinrich, and S B Kaye, and P H de Mulder, and A van Oosterom, and R Paridaens, and J B Vermorken, and J Wanders, and H Franklin, and M Bayssas
Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC.
January 1994, European journal of cancer (Oxford, England : 1990),
U Bruntsch, and B Heinrich, and S B Kaye, and P H de Mulder, and A van Oosterom, and R Paridaens, and J B Vermorken, and J Wanders, and H Franklin, and M Bayssas
Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study.
August 1994, British journal of cancer,
U Bruntsch, and B Heinrich, and S B Kaye, and P H de Mulder, and A van Oosterom, and R Paridaens, and J B Vermorken, and J Wanders, and H Franklin, and M Bayssas
Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center.
January 1995, European journal of cancer (Oxford, England : 1990),
U Bruntsch, and B Heinrich, and S B Kaye, and P H de Mulder, and A van Oosterom, and R Paridaens, and J B Vermorken, and J Wanders, and H Franklin, and M Bayssas
Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group.
February 1994, Annals of oncology : official journal of the European Society for Medical Oncology,
U Bruntsch, and B Heinrich, and S B Kaye, and P H de Mulder, and A van Oosterom, and R Paridaens, and J B Vermorken, and J Wanders, and H Franklin, and M Bayssas
Phase II trial of anaxirone (TGU) in advanced colorectal cancer: an EORTC Early Clinical Trials Group (ECTG) study.
January 1994, European journal of cancer (Oxford, England : 1990),
U Bruntsch, and B Heinrich, and S B Kaye, and P H de Mulder, and A van Oosterom, and R Paridaens, and J B Vermorken, and J Wanders, and H Franklin, and M Bayssas
Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview.
November 1997, European journal of cancer (Oxford, England : 1990),
Copied contents to your clipboard!